Contineum Therapeutics Files 8-K
Ticker: CTNM · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Contineum Therapeutics filed an 8-K on 9/18/25 covering disclosures and financials.
AI Summary
Contineum Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting on various events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Pipeline Therapeutics, Inc. until April 5, 2021, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides updates on company events and financial information, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Registrant
- September 18, 2025 (date) — Date of Report
- Pipeline Therapeutics, Inc. (company) — Former Company Name
- April 5, 2021 (date) — Date of Name Change
- San Diego, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Contineum Therapeutics, Inc.?
The 8-K filing serves to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits as of September 18, 2025.
When did Contineum Therapeutics, Inc. change its name from Pipeline Therapeutics, Inc.?
Contineum Therapeutics, Inc. changed its name from Pipeline Therapeutics, Inc. on April 5, 2021.
Where are Contineum Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Contineum Therapeutics, Inc. are located at 3565 General Atomics Court, Suite 200, San Diego, California.
What is the state of incorporation for Contineum Therapeutics, Inc.?
Contineum Therapeutics, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Contineum Therapeutics, Inc.?
The IRS Employer Identification Number for Contineum Therapeutics, Inc. is 27-1467257.
Filing Stats: 1,129 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2025-09-18 08:16:26
Key Financial Figures
- $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
Filing Documents
- ctnm20250910_8k.htm (8-K) — 37KB
- ex_860445.htm (EX-99.1) — 15KB
- ex_862024.htm (EX-99.2) — 6KB
- logo.jpg (GRAPHIC) — 8KB
- slide01.jpg (GRAPHIC) — 40KB
- slide02.jpg (GRAPHIC) — 138KB
- slide03.jpg (GRAPHIC) — 77KB
- slide04.jpg (GRAPHIC) — 61KB
- slide05.jpg (GRAPHIC) — 40KB
- slide06.jpg (GRAPHIC) — 47KB
- slide07.jpg (GRAPHIC) — 75KB
- slide08.jpg (GRAPHIC) — 43KB
- slide09.jpg (GRAPHIC) — 40KB
- 0001437749-25-029349.txt ( ) — 981KB
- ctnm-20250918.xsd (EX-101.SCH) — 3KB
- ctnm-20250918_def.xml (EX-101.DEF) — 12KB
- ctnm-20250918_lab.xml (EX-101.LAB) — 15KB
- ctnm-20250918_pre.xml (EX-101.PRE) — 12KB
- ctnm20250910_8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and certain materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company's clinical trial and product development plans and timelines, including, but not limited to, those regarding the pharmacological properties, safety, tolerability and therapeutic potential of PIPE-791; the potential of the data from the Company's Phase 1b PET trial to predict dose selection, including whether the Company's planned dose selection for its future Phase 2 proof-of-concept clinical trials will exceed 90% target coverage at trough with once daily dosing, or to predict future clinical outcomes or results. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company's product candidate development activities and planned clinical trials; the Company's ability to execute on its strategy; positive results from any of its clinical studies may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the Company's ability to fund operations. Additional risks and uncertainties that could affect the Company's business, operations and results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) f
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated September 18, 2025. 99.2 PIPE-791 Phase 1b PET Trial Topline Data Supplemental Information slide presentation of Contineum Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2025 Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Principal Financial Officer and Principal Accounting Officer